Mid Pharmaceuticals
Market Cap
₹54,369 ₹54,369 Cr.
P/E
33.67
PEG
3.21
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- Revenue deceleration from 14% to 8.1% reflects competitive proliferation; the base case assumes stabilization as the NPI pipeline and Extensior distribution partnership contribute growth, but the bear case activates if quarterly YoY growth stays below 6% and Extensior adoption falters.- Execution risk concentrates in unproven revenue vectors: NPI and partnership contributions must scale from 5% to 15% of revenue — if Extensior generates <₹100 Cr in FY27, the bear case becomes the primary scenario.
- Extensior adds a revenue catalyst but dilutes blended margins given its distribution-model economics, capping EBITDA margin expansion to ~70bps over five years despite a richer product mix.

Key Ratios

Debt to Equity
Debt to Equity
-
Div Yield (%)
Div Yield (%)
2.56
Individual < 2 lac
Individual < 2 lac
13.31 %
Institutions
Institutions
9.16 %
Market cap
Market cap
54,369 Cr
No. of Shareholders
No. of Shareholders
78,320
OPM (%)
OPM (%)
28.11 %
PE
PE
33.67
Prom Holding
Prom Holding
74.99 %
ROCE (%)
ROCE (%)
42.09
ROE (%)
ROE (%)
32.51
Sales
Sales
7,004 Cr
  • Abbott India
  • Ipca Laboratories
  • Gland Pharma
  • TJI Pharma
Last updated on 10 Sep 2026
  • Abbott India sells pharmaceuticals in a single reported segment. Its portfolio spans GI, Women's Health, Metabolics, CNS, Vaccines and Multi-specialty with brands Thyronorm, Duphaston, Vertin, Arachitol and Extensior.
  • Profit comes from its core therapy franchises. Extensior semaglutide is the early growth leg with no sales disclosed yet.
  • Management is shifting the mix toward chronic, sub-chronic and preventive care. Extensior semaglutide commercialisation with Novo Nordisk is intended to build its GLP-1 presence.
  • It operates with no debt and holds large cash balances. It returns most profit as dividends.
  • Near-term earnings still depend on the core franchises. Extensior has no disclosed sales yet and is readable only at company level.
  • Extensior launch progress No stated timeline
    First disclosed sales show whether GLP-1 broadens the metabolic portfolio.
  • Labour Codes state-rules finalisation No stated timeline
    The outcome settles the final liability against the FY26 net Rs18.1 Cr charge.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
25135
52W Range
High
31400
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

3 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

0 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.67 %
(as of Jul 22)
Anti-Infectives - Market Share
0.02 %
(as of Nov 20)
Antineo Plastic - Market Share
1.96 %
(as of May 19)
Blood Related - Market Share
0.32 %
(as of Jul 22)
Cardiovascular - Market Share
32.40 %
(as of Mar 19)
Creon - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Acute vs Chronic

Dosage Form Break-Up

Brand Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Brands

    Brufen
    Cremaffin Plus
    Digene
    Duphalac
    Duphaston
    Thyronorm
    Zolfresh

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • Suven Life Sciences Ltd.
    • IOL Chemicals And Pharmaceuticals Ltd.
    • Aarti Drugs Ltd.
    • TCPL Packaging Ltd.
    • TCI Express Ltd.

    FAQs on Abbott India Ltd. Business

    Abbott India Limited, a subsidiary of Abbott Laboratories, is a leading pharmaceutical company in India offering a wide range of high-quality medicines in various therapeutic categories with a focus on product development and clinical support.

    Abbott India major competitors are Ipca Laboratories, Gland Pharma, Glaxosmithkline Phar, Alkem Laboratories, Ajanta Pharma, Glenmark Pharma., Wockhardt.
    Market Cap of Abbott India is ₹53,601 Crs.
    While the median market cap of its peers are ₹47,988 Crs.

    Abbott India seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation
    Conference Call Sep
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material